ClinicalTrials.gg
RecruitingNCT05927454AcostillUpdated Feb 12, 2026

Acostill ( RaDiCo Cohort) (RaDiCo Acostill)

An observational study in Still Disease, Still's Disease, Adult-Onset and Still Disease, Juvenile Onset, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Observational

How we know

From the registry’s dates

  • Started Jul 2017; still recruiting 9 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Arthritis, Juvenile with a site in France — 18 open to participants now, 21 under way, 9 of them phase 3. Arthritis, Juvenile · France.

Planned enrollment
6th of 21
500 · median 274
Started
2017
with 4 others
Observational
21 of 71
5 open now
Primary completion
2027-07
later than 7 of 20 live
Registered
56th of 71
by date
Lead sponsor
3 of 71
Institut National de la Santé Et de la Recherche Médicale, France

Among the 71 studies in Arthritis, Juvenile with a site in France, this one is the 6th largest by planned enrollment of the 21 observational ones that give a count, is one of 5 that started in 2017, is one of 21 observational ones, reaches primary completion later than 7 of the 20 other live ones, and was the 56th registered.

Arthritis, Juvenile

367 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

18 of the 71 studies in Arthritis, Juvenile with a site in France are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Arthritis, Juvenile with a site in France, or all of them as a file.
02

Study summary

Adult Onset Still Disease (AOSD) and Systemic onset Juvenile Idiopathic Arthritis (SoJIA) are two rare multifactorial diseases associated with systemic inflammation. These two forms AOSD and SoJIA are considered to be two facets of the same syndrome, combining four cardinal symptoms [hectic fever> 39 °, arthralgia or arthritis, skin rash, a leukocyte formula with more than 80% of neutrophils]; lymphadenopathy and splenomegaly may also be found. There is an important biological inflammatory syndrome with elevation of the reactive C protein, of serum ferritin with a dramatic drop in the glycosylated fraction. The incidence of the disease is low, around 0.1/100,000 for adults and 0.6/100,000 for children. Its prevalence is approximately 1 to 3/100,000 and 3/100,000 for children, so there are approximately 500 to 1,500 adults and 450 children affected in France. It is subdivided into pediatric and adult forms according to the age of onset before or after 16 years. The prognosis of the disease is functional and vital. Macrophage activation syndrome (SAM) is frequently associated with either the onset of the disease or the initiation of treatment or concomitantly with viral reactivation. The course over time has mainly been studied in children and is variable: regression, course by flare-ups with term regression and chronic joint development. In adults we can also observe these 3 evolutionary modes. However, differences seem to exist between AOSD and SoJIA.

The various clinical questions posed by this disease are as follows:

  • Why does it differentially affect two age groups of the population?
  • Why is the clinical expression heterogeneous with pure systemic or articular forms, the frequency of SAM, and rare organ damage?
  • Why is the evolution over time different with resolving monocyclic forms or polycyclic forms and sometimes chronic evolutions?

These differences could be explained by distinct underlying pathogenic mechanisms. But at present, the pathophysiology of this entity remains unknown, although several hypotheses can be formulated involving several pathophysiological pathways.

The pathogenesis of Still's disease has not yet been elucidated but there is a significant inflammatory reaction without the production of autoantibodies, which makes this disease a form of autoinflammatory syndrome with abnormalities of the innate immunity (activation of macrophages, strong elevations of pro-inflammatory cytokines: interleukins 1 and 18, possible abnormalities of inflammasomes and NK cells). The treatment is based on anti-inflammatory drugs, corticosteroids with the usefulness of methotrexate and anti-TNF in the event of significant joint damage. Interleukin 1 and 6 inhibitors have been shown to be effective in this disease. In adults and children, there are forms that are refractory to treatment, with a risk of AA amyloidosis for these patients.

The expected outcomes of this work are to improve knowledge of Still disease and patient management on the following aspects:

  • Comparison of pediatric and adult forms (which has never been done on a large number of patients),
  • Better understanding of the pathogenic mechanisms of the disease,
  • The identification of early diagnostic/prognostic markers,
  • The possibility of promoting the evaluation of new therapies to come thanks to the constitution of an active file of patients with a standardized follow-up.

The ACOSTILL study group is thus a unique collaboration of adult clinicians (rheumatologists and internists) and pediatricians, who have decided to unite their efforts to increase knowledge about the pathogenesis of Still disease in order to better understand the disease and improve care pathways. Many of them participated in the development of the national diagnostic and care protocol published in 2018.

03

Conditions studied

  • Still Disease
  • Still's Disease, Adult-Onset
  • Still Disease, Juvenile Onset

Keywords

  • Still Disease
  • Rare disease
  • Diagnostic markers
  • Prognostic markers
  • New therapies
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

In order to reflect the reality of daily practice, all pediatric and adult patients already diagnosed and monitored (prevalent patients) or newly diagnosed (incident patients) in one of the French Rare Disease Reference Center or Rare Disease Competence Center will be invited. to participate in the study. In order to document the improvement in patient care, morbidity and mortality through the implementation of the PNDS Still, deceased patients may be included in the cohort.

The objective is to recruit a minimum of 200 adult patients and 300 pediatric patients so that the study has sufficient statistical power. The stratification of patients is made into 4 subgroups according to the form of the pathology:

  • Pediatric (juvenile arthritis systemic idiopathic)
  • Adult monocyclic (approximately 30% of cases)
  • Adult intermittent or polycyclic (30%)
  • Adult persistent or chronic (40%)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged over 16 (age> 16) meeting the diagnostic criteria of Yamaguchi or Fautrel criteria (appendix 5)
  • Aged 16 years or less (age ≤16 years) fulfilling the 2001 criteria for ILAR systemic form of juvenile idiopathic arthritis
  • Having signed a consent to participate in the cohort and in the collection of clinical and biological data; in accordance with the regulations, for patients who are minors or adults who are protected, the non-opposition of the legal representatives will be sought.
  • Affiliated to the "Régime National d'Assurance Maladie".

Exclusion criteria

Exclusion Criteria:

  • Other cause of relapsing infectious fever (such as tuberculosis, toxoplasmosis, deep abscesses, viroses, sepsis) or tumor (such as lymphomas)
  • Other defined inflammatory rheumatism such as rheumatoid arthritis, psoriatic arthritis, spondyloarthropathies.
  • inflammatory disease (systemic lupus erythematosus), granulomatosis (sarcoidosis, Blau syndrome), vasculitis (Behçet's disease, nodular arteritis), polymyositis and dermatomyositis.
  • Well-defined auto-inflammatory syndromes with unambiguous mutations, such as familial Mediterranean fever, cryopyrinopathies, TRAPS, mevalonate kinase deficiency.
  • Known macrophage activation syndromes of genetic origin.
  • Patients unable to understand the information leaflet and sign the form
  • Patients not affiliated to the "Régime National d'Assurance Maladie"
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. General signs of the disease

    Time frame: Through study completion, at 1 year, 2 year, 3 year, 4 year, 5 year

  2. Clinical signs of the disease

    Time frame: Through study completion, at 1 year, 2 year, 3 year, 4 year, 5 year

  3. Biological results

    Time frame: Through study completion, at 1 year, 2 year, 3 year, 4 year, 5 year

  4. - The impact of the disease on the patient's daily life

    Time frame: Through study completion, at 1 year, 2 year, 3 year, 4 year, 5 year

Secondary outcomes

  1. Quality of life scores

    Measurement of changes in quality of life scores obtained throughout the study

    Time frame: Through study completion, at 1 year, 2 year, 3 year, 4 year, 5 year

  2. AIDAI scores

    Measurement of the individual evolution of the AIDAI (Validation of the Auto-Inflammatory Diseases Activity Index) scores obtained throughout the study

    Time frame: Through study completion, at 1 year, 2 year, 3 year, 4 year, 5 year

  3. Prospective biomarkers

    Search for an association between the prospective biomarkers (pro and anti-inflammatory cytokines, AAS, S100 protein, soluble CD163, ferritinemia and glycosylated ferritinemia) and the diagnosis made (different clinical forms of Still's disease)

    Time frame: Through study completion, at 1 year, 2 year, 3 year, 4 year, 5 year

  4. Presence of autoinflammatory disease in relatives

    Construction of a family tree based on the presence of autoinflammatory disease in relatives

    Time frame: Through study completion, at 1 year, 2 year, 3 year, 4 year, 5 year

07

Study locations

1 of 1 sites recruiting
  • RaDiCo-AcoStill
    Paris, Île-de-France Region 75012, France
    Recruiting
    • Sonia Gueguen, PHD · Contactsonia.gueguen@radico.fr · 0033 6 88 34 54 08
    • Sophie Georgin-Lavialle, PHD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2017 (actual). Primary completion is estimated for Jul 2027, 120 months after the start.

Of 43 observational studies under Arthritis, Juvenile, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 186. This study's planned 120 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2021
First posted
Jul 3, 2023
StartActual
Jul 11, 2017
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05927454
Responsible party
Sponsor
First posted
Jul 3, 2023
Start date
Jul 11, 2017
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Feb 12, 2026

Study contacts

Sophie Georgin-Lavialle, PHD
Contact
sophie.georgin-lavialle@aphp.fr
0033 156017447
Bruno Fautrel, PHD
Contact
bruno.fautrel@aphp.fr
Sophie Georgin-Lavialle, PHD
principal investigator · INSERM U933

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion